Clinical Trial

Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer

Study acronym: SKYLINE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 6, 2026 (before its estimated August 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase II study, preceded by a safety run-in, with two independent cohorts (cohort A in early Triple Negative Breast Cancer (TNBC) patients and cohort B in late in metastatic TNBC patients) designed to evaluate the efficacy of atezolizumab, tiragolumab and chemotherapy.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-12-15; most recent amendment 2026-02-04.
Status change: Recruiting → Active, Not Recruiting 2026-02-04
Status change: Not Yet Recruiting → Recruiting 2024-03-01
Trial Details
NCT Number NCT06175390
Lead Sponsor Institut Curie
Collaborators: Hoffmann-La Roche
Conditions Triple Negative Breast Cancer
Enrollment 81 participants
Start Date 2024-03-27
Primary Completion 2026-08-15 (estimated)
Study Completion 2029-02-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-06